Does aging weaken neuronal protein-quality-control systems and promote amyloid-beta and tau accumulation?

Aging is associated with impaired cellular protein handling in the brain, a process highly relevant to Alzheimer-type pathology and neuronal vulnerability. The overall claim is directionally well supported, but its broad wording should be understood as describing susceptible cells and pathways rather than a uniform failure in every neuron.

Clinical and experimental evidence

• Proteasome activity declines with age and is reduced in Alzheimer brain tissue, although human measurements are largely bulk post-mortem assays rather than neuron-specific functional studies.
• Directional animal evidence supports causality: proteasome inhibition in 3xTg-AD mice increased amyloid-beta (Aβ) and tau burden. In aged mice, neuronal overexpression of the proteasome subunit PSMB5 improved spatial learning and memory, linking local protein clearance to synaptic maintenance.
• Impaired lysosomal capacity also promotes Aβ pathology: heterozygous loss of several lysosomal-enzyme genes increased brain-interstitial Aβ40 and plaque burden in AD-model mice.
• Defective autophagic–lysosomal processing can reduce disposal of misfolded or hyperphosphorylated tau, favoring its persistence and aggregation.

Mechanistic interpretation

• Autophagy delivers cytoplasmic cargo to lysosomes; defects in autophagosome maturation, transport, fusion, acidification, or lysosomal degradation can stall this flux.
• Aβ and tau may then amplify the problem: pathogenic Aβ impairs endolysosomal integrity, while phosphorylated tau can disrupt autophagosome transport and fusion. This creates a potentially self-reinforcing cycle of impaired clearance and proteotoxic accumulation.
• Lysosomal damage and defective repair in human neuron-derived models, together with neuritic degeneration in AD tissue, support reduced clearance as a contributor to lower capacity to withstand later cellular stress.

Bottom line

• Aging plausibly weakens proteasomal and autophagic–lysosomal quality control in particular neuronal populations, promoting Aβ and tau accumulation and likely reducing neuronal resilience. The effects are cell-, brain-region-, and pathway-specific; human evidence does not establish a universal or strictly one-way age-to-pathology sequence.